Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma

Jun ichi Kuratsu, Kimio Yoshizato, Teizo Yoshimura, Edward J. Leonard, Hideo Takeshima, Yukitaka Ushio

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Monocyte chemoattractant protein-1 (MCP-1) is a 76-amino acid protein that attracts monocytes. In vitro studies have reported high levels of MCP-1 messenger RNA expression, as well as the presence of MCP-1, in malignant glioma cells. Purpose: Our purpose was to determine whether an MCP-1 assay could be used in a clinical setting 1) to differentiate malignant from benign gliomas and from nontumor disorders of the central nervous system and 2) to detect subarachnoid dissemination of glioma cells. Methods: MCP-1 levels in cerebrospinal fluid (CSF) and cyst fluid were measured with a sandwich enzyme-linked immunosorbent assay (ELISA) that we had previously developed. We measured MCP-1 levels in CSF samples from 19 patients with malignant glioma (glioblastoma, 10; anaplastic astrocytoma, six; anaplastic oligodendroglioma, two; and ependymoblastoma, one), nine patients with benign glioma, and seven patients with nontumor disorders of the central nervous system. Cyst fluids from four patients with malignant glioma (anaplastic astrocytoma) were also tested. The correlation between MCP-1 concentration in the CSF and subarachnoid dissemination of malignant glioma cells was also studied. Results: The MCP-1 concentration (mean ± SE) in CSF samples from patients with malignant glioma (2.3 ± 0.4 ng/mL) was significantly higher than that from patients with benign glioma (0.6 ± 0.1 ng/mL) (P

Original languageEnglish
Pages (from-to)1836-1839
Number of pages4
JournalJournal of the National Cancer Institute
Volume85
Issue number22
DOIs
Publication statusPublished - Nov 17 1993
Externally publishedYes

Fingerprint

Monocytes
Cerebrospinal fluid
Cyst Fluid
Chemokine CCL2
Glioma
Cerebrospinal Fluid
Proteins
Protein
Fluid
Fluids
Central Nervous System Diseases
Astrocytoma
Neurology
Disorder
Assays
Cell
Oligodendroglioma
Enzyme-linked Immunosorbent Assay
Primitive Neuroectodermal Tumors
Sandwich

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Cancer Research

Cite this

Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. / Kuratsu, Jun ichi; Yoshizato, Kimio; Yoshimura, Teizo; Leonard, Edward J.; Takeshima, Hideo; Ushio, Yukitaka.

In: Journal of the National Cancer Institute, Vol. 85, No. 22, 17.11.1993, p. 1836-1839.

Research output: Contribution to journalArticle

Kuratsu, Jun ichi ; Yoshizato, Kimio ; Yoshimura, Teizo ; Leonard, Edward J. ; Takeshima, Hideo ; Ushio, Yukitaka. / Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. In: Journal of the National Cancer Institute. 1993 ; Vol. 85, No. 22. pp. 1836-1839.
@article{3addda6a427d45499136a9971699eff6,
title = "Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma",
abstract = "Background: Monocyte chemoattractant protein-1 (MCP-1) is a 76-amino acid protein that attracts monocytes. In vitro studies have reported high levels of MCP-1 messenger RNA expression, as well as the presence of MCP-1, in malignant glioma cells. Purpose: Our purpose was to determine whether an MCP-1 assay could be used in a clinical setting 1) to differentiate malignant from benign gliomas and from nontumor disorders of the central nervous system and 2) to detect subarachnoid dissemination of glioma cells. Methods: MCP-1 levels in cerebrospinal fluid (CSF) and cyst fluid were measured with a sandwich enzyme-linked immunosorbent assay (ELISA) that we had previously developed. We measured MCP-1 levels in CSF samples from 19 patients with malignant glioma (glioblastoma, 10; anaplastic astrocytoma, six; anaplastic oligodendroglioma, two; and ependymoblastoma, one), nine patients with benign glioma, and seven patients with nontumor disorders of the central nervous system. Cyst fluids from four patients with malignant glioma (anaplastic astrocytoma) were also tested. The correlation between MCP-1 concentration in the CSF and subarachnoid dissemination of malignant glioma cells was also studied. Results: The MCP-1 concentration (mean ± SE) in CSF samples from patients with malignant glioma (2.3 ± 0.4 ng/mL) was significantly higher than that from patients with benign glioma (0.6 ± 0.1 ng/mL) (P",
author = "Kuratsu, {Jun ichi} and Kimio Yoshizato and Teizo Yoshimura and Leonard, {Edward J.} and Hideo Takeshima and Yukitaka Ushio",
year = "1993",
month = "11",
day = "17",
doi = "10.1093/jnci/85.22.1836",
language = "English",
volume = "85",
pages = "1836--1839",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "22",

}

TY - JOUR

T1 - Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma

AU - Kuratsu, Jun ichi

AU - Yoshizato, Kimio

AU - Yoshimura, Teizo

AU - Leonard, Edward J.

AU - Takeshima, Hideo

AU - Ushio, Yukitaka

PY - 1993/11/17

Y1 - 1993/11/17

N2 - Background: Monocyte chemoattractant protein-1 (MCP-1) is a 76-amino acid protein that attracts monocytes. In vitro studies have reported high levels of MCP-1 messenger RNA expression, as well as the presence of MCP-1, in malignant glioma cells. Purpose: Our purpose was to determine whether an MCP-1 assay could be used in a clinical setting 1) to differentiate malignant from benign gliomas and from nontumor disorders of the central nervous system and 2) to detect subarachnoid dissemination of glioma cells. Methods: MCP-1 levels in cerebrospinal fluid (CSF) and cyst fluid were measured with a sandwich enzyme-linked immunosorbent assay (ELISA) that we had previously developed. We measured MCP-1 levels in CSF samples from 19 patients with malignant glioma (glioblastoma, 10; anaplastic astrocytoma, six; anaplastic oligodendroglioma, two; and ependymoblastoma, one), nine patients with benign glioma, and seven patients with nontumor disorders of the central nervous system. Cyst fluids from four patients with malignant glioma (anaplastic astrocytoma) were also tested. The correlation between MCP-1 concentration in the CSF and subarachnoid dissemination of malignant glioma cells was also studied. Results: The MCP-1 concentration (mean ± SE) in CSF samples from patients with malignant glioma (2.3 ± 0.4 ng/mL) was significantly higher than that from patients with benign glioma (0.6 ± 0.1 ng/mL) (P

AB - Background: Monocyte chemoattractant protein-1 (MCP-1) is a 76-amino acid protein that attracts monocytes. In vitro studies have reported high levels of MCP-1 messenger RNA expression, as well as the presence of MCP-1, in malignant glioma cells. Purpose: Our purpose was to determine whether an MCP-1 assay could be used in a clinical setting 1) to differentiate malignant from benign gliomas and from nontumor disorders of the central nervous system and 2) to detect subarachnoid dissemination of glioma cells. Methods: MCP-1 levels in cerebrospinal fluid (CSF) and cyst fluid were measured with a sandwich enzyme-linked immunosorbent assay (ELISA) that we had previously developed. We measured MCP-1 levels in CSF samples from 19 patients with malignant glioma (glioblastoma, 10; anaplastic astrocytoma, six; anaplastic oligodendroglioma, two; and ependymoblastoma, one), nine patients with benign glioma, and seven patients with nontumor disorders of the central nervous system. Cyst fluids from four patients with malignant glioma (anaplastic astrocytoma) were also tested. The correlation between MCP-1 concentration in the CSF and subarachnoid dissemination of malignant glioma cells was also studied. Results: The MCP-1 concentration (mean ± SE) in CSF samples from patients with malignant glioma (2.3 ± 0.4 ng/mL) was significantly higher than that from patients with benign glioma (0.6 ± 0.1 ng/mL) (P

UR - http://www.scopus.com/inward/record.url?scp=0027443077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027443077&partnerID=8YFLogxK

U2 - 10.1093/jnci/85.22.1836

DO - 10.1093/jnci/85.22.1836

M3 - Article

C2 - 8230263

AN - SCOPUS:0027443077

VL - 85

SP - 1836

EP - 1839

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 22

ER -